ARCTURUS THERAPEUTICS Reports 64.7% Drop in Revenue for Second Quarter of FY2023

August 22, 2023

🌧️Earnings Overview

For the second quarter of their fiscal year 2023, ARCTURUS THERAPEUTICS ($NASDAQ:ARCT) reported a total revenue of USD 9.6 million, a decrease of 64.7% from the same period in the prior year. Their net income for the quarter was USD -52.6 million, compared to -21.6 million in the second quarter of FY2022.


GoodWhale has recently conducted a comprehensive analysis of ARCTURUS THERAPEUTICS‘s wellbeing. After evaluating the company’s financial and business aspects, GoodWhale has identified ARCTURUS THERAPEUTICS as a medium risk investment. As part of their analysis, GoodWhale has detected four risk warnings in the income sheet, balance sheet, cashflow statement and financial journal. For more detailed information, it is advised to register with GoodWhale in order to gain access to the full report. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Arcturus Therapeutics. More…

    Total Revenues Net Income Net Margin
    262.71 80.28 23.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Arcturus Therapeutics. More…

    Operations Investing Financing
    132.79 -7.04 -30.72
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Arcturus Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    430.65 145.47 10.73
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Arcturus Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    185.8% 32.2%
    FCF Margin ROE ROA
    47.9% 17.2% 12.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The Company’s mRNA technology is based on modification of the genetic code of living cells to express proteins that are missing or defective due to genetic diseases. Arcturus has developed proprietary technologies for the delivery of nucleic acids including Messenger RNA (mRNA). The Company’s technology platforms include LUNAR and STARR. Arcturus Therapeutics‘ competitors include BioNTech SE, Pfizer Inc, and Moderna Inc.

    – BioNTech SE ($NASDAQ:BNTX)

    As of 2022, BioNTech SE has a market cap of 33.27B and a Return on Equity of 63.88%. The company is a biotechnology company that develops and manufactures innovative immunotherapies and vaccines for the treatment of cancer and other diseases.

    – Pfizer Inc ($NYSE:PFE)

    Pfizer Inc is a biopharmaceutical company with a market cap of 255.87B as of 2022. The company has a Return on Equity of 27.06%. Pfizer Inc researches, develops, manufactures, and markets pharmaceutical products worldwide. The company offers products in various therapeutic areas, such as inflammation and immunology, cardiovascular, neuroscience and pain, oncology and hematology, vaccines, and consumer healthcare.

    – Moderna Inc ($NASDAQ:MRNA)

    As of 2022, Moderna Inc has a market cap of 55.55B and a Return on Equity of 55.93%.

    Moderna Inc is a biotechnology company that specializes in the development and manufacturing of vaccines and therapeutics. The company’s products include vaccines for human papillomavirus, influenza, and other diseases. Moderna Inc also manufactures therapeutics for the treatment of cancer and other conditions.


    Arcturus Therapeutics has had a difficult second quarter of FY2023. Revenue has decreased by 64.7% compared to the same period the previous year, resulting in a net loss of USD -52.6 million, an increase from -21.6 million in the same quarter of the prior year. This is of concern to investors, as the company’s financial health appears to be declining. It is therefore important for investors to closely monitor the company’s performance in the coming quarters to determine if there are any positive changes in their financial situation.

    Recent Posts

    Leave a Comment